Research Firm Seeks FDA Approval Transparency

An influential drug pricing research firm, the Institute for Clinical and Economic Review (ICER), is calling for greater transparency from the U.S. Food and Drug Administration (FDA) regarding its accelerated approval process for certain drugs. The report suggests that clearer communication and more open procedures are needed when granting these expedited approvals. This recommendation aims to enhance public trust and understanding of the drug approval system, particularly for medications intended for serious conditions.